News & Events
Published On: 3/17/2020
TARGET PharmaSolutions Expands TARGET-DERM Research Community with Two New Industry Partnerships
Real-world clinical data company, TARGET PharmaSolutions Inc., announced today new partnerships with two multinational pharmaceutical corporations to support the TARGET-DERM observational study. They join current partner Novartis in support of this collaboration to evaluate adult and pediatric patients with atopic dermatitis (eczema) and other immune-mediated inflammatory skin conditions.
“The two new collaborative industry partnerships are evidence that TARGET’s real-world data is extremely valuable to the dermatology community,” said TARGET PharmaSolutions CEO, Neal Bibeau. “These companies join TARGET in our commitment to improving patient lives, and we are thrilled to play a key role in helping to inform their future direction with a base of strong scientific evidence.”
TARGET’s real-world database enrolls consented patients across a variety of community and academic sites to collect the structured and unstructured medical record data needed to inform optimal and individual treatment approaches. The real-world data can be utilized throughout the pharmaceutical development and commercialization process.
“The longitudinal, real-world data that TARGET-DERM is collecting will help to shape understanding of the natural history of atopic dermatitis,” said TARGET-DERM Steering Committee Co-Chair, Emma Guttman-Yassky, MD, PhD, professor and vice chair for research in the Department of Dermatology at the Icahn School of Medicine at Mount Sinai Medical Center. “It will also capture important treatment safety and effectiveness of new agents across populations as they come to market.”
Launched in 2019, TARGET-DERM is the sixth disease community created by TARGET since 2015. The first disease community launched by the company, TARGET-NASH, is currently in its fourth year of data collection. Other ongoing TARGET studies include hepatocellular carcinoma (HCC), inflammatory bowel disease (IBD), primary biliary cholangitis (PBC) and chronic hepatitis B (HBV). TARGET-ASTHMA is the newest community developed.
To create each real-world community, the TARGET model organizes groups of stakeholders around specific diseases to produce regulatory-grade data and analysis on the disease’s natural history, current treatment paradigms, and patient outcomes. This includes key scientific leaders, regulatory agencies, pharmaceutical manufacturers, and patient advocacy groups who are responsible in answering strategic questions and determining the study’s structure.
About Target RWE
Target RWE is a leading health evidence solutions company that generates innovative real-world evidence (RWE) and provides scientific intelligence tools and solutions for pharmaceutical, biotechnology, and other healthcare partners. Specifically designed to address the complexities of the natural history of disease, the drug development process and treatments in real-world settings, Target RWE builds regulatory-grade clinical data sets and applies state of the science epidemiologic methods to produce RWE about patients with specific conditions, symptoms, and therapies used in usual clinical practice.
Target RWE's regulatory-grade data sets and evidence, modern epidemiological methods, and sound scientific principles rendered as software can be utilized to better health outcomes, inform patient health guidelines, and improve overall quality of care. For more information, visit www.targetrwe.com.
984.234.0268 ext 205
10/11/2021Target RWE Inflammatory Bowel Disease Research Presented at UEG Week 2021
09/13/2021Update from Paris NASH 2021: New Target RWE Nonalcoholic Steatohepatitis (NASH) Data Presented at This Year’s Meeting
07/01/2021Target RWE HBV Research on Antiviral Treatments, Characteristics, and Clinical Outcomes Published in Digestive Diseases and Sciences
06/29/2021Liver International Publishes Hepatocellular Carcinoma RWE Review
06/22/2021Target RWE Study Shows Significant Differences in Medication Use Among Older Patients with IBD Compared to Younger Patients